LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα.

    Tittes, Julia / Brell, Jennifer / Fritz, Pia / Jonak, Constanze / Stary, Georg / Ressler, Julia M / Künig, Sarojinidevi / Weninger, Wolfgang / Stöckl, Johannes

    Dermatology and therapy

    2024  Volume 14, Issue 3, Page(s) 613–626

    Abstract: Introduction: Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. ... ...

    Abstract Introduction: Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. The effects of these treatments on immune cell populations in the skin are largely unknown.
    Methods: In this study, we compared the composition of cutaneous, lesional and non-lesional immune cells and blood immune cells in ixekizumab- or adalimumab-treated patients with psoriasis.
    Results: Our data reveal that both treatments efficiently downregulate T cells, macrophages and different subsets of dendritic cells (DCs) in lesional skin towards levels of healthy skin. In contrast to lesional skin, non-lesional areas in patients harbor only few or no detectable DCs compared to the skin of healthy subjects. Treatment with neither ixekizumab nor adalimumab reversed this DC imbalance in non-lesional skin of psoriatic patients.
    Conclusion: Our study shows that anti-IL-17A and anti-TNFα therapy rebalances the immune cell repertoire of lesional skin in psoriatic patients but fails to restore the disturbed immune cell repertoire in non-lesional skin.
    Language English
    Publishing date 2024-03-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2680284-3
    ISSN 2190-9172 ; 2193-8210
    ISSN (online) 2190-9172
    ISSN 2193-8210
    DOI 10.1007/s13555-024-01112-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

    Taylor, Amelia M / McKeown, Janet / Dimitriou, Florentia / Jacques, Sarah K / Zimmer, Lisa / Allayous, Clara / Yeoh, Hui-Ling / Haydon, Andrew / Ressler, Julia M / Galea, Claire / Woodford, Rachel / Kahler, Katharina / Hauschild, Axel / Festino, Lucia / Hoeller, Christoph / Schwarze, Julia K / Neyns, Bart / Wicky, Alexandre / Michielin, Olivier /
    Placzke, Joanna / Rutkowski, Piotr / Johnson, Douglas B / Lebbe, Celeste / Dummer, Reinhard / Ascierto, Paolo A / Lo, Serigne / Long, Georgina V / Carlino, Matteo S / Menzies, Alexander M

    European journal of cancer (Oxford, England : 1990)

    2024  Volume 199, Page(s) 113561

    Abstract: Background: Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant therapy may ...

    Abstract Background: Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant therapy may be suitable for 'second adjuvant' treatment after local therapy. We sought to examine the efficacy and safety of 'second adjuvant' BRAF/MEKi.
    Patients and methods: Patients with BRAFmut melanoma treated with adjuvant PD-1 based immunotherapy who recurred, underwent definitive local therapy and were then treated with adjuvant BRAF/MEKi were identified retrospectively from 13 centres (second adjuvant group). Demographics, disease and treatment characteristics and outcome data were examined. Outcomes were compared to BRAFmut patients who did not receive 'second adjuvant' therapy (no second adjuvant group).
    Results: 73 patients were included; 61 who received 'second adjuvant' therapy and 12 who did not. Most initially recurred on PD-1 therapy (66%). There were no differences in characteristics between groups. 92% of second adjuvant group received dabrafenib and trametinib and median duration of therapy was 11.8 months (0.4, 34.5). 72% required dose adjustments, 23% had grade 3 + toxicity and 38% permanently discontinued drug due to toxicity. After median 26.1 months (1.9, 56.3) follow-up, recurrence-free survival (RFS) was improved in second adjuvant group versus no second adjuvant group (median 30.8 vs 4 months, HR 0.35; p = 0.014), largely driven by a delay in early recurrence, with no difference in overall survival (p = 0.59).
    Conclusion: This is the first study examining outcomes of 'second adjuvant' targeted therapy for melanoma, after failure of adjuvant PD-1 based immunotherapy. Data suggest a short-term improvement in RFS, but at the cost of toxicity. Alternative strategies and more data on sequencing adjuvant therapies are required to improve outcomes.
    MeSH term(s) Humans ; Melanoma/drug therapy ; Proto-Oncogene Proteins B-raf/genetics ; Programmed Cell Death 1 Receptor/therapeutic use ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Skin Neoplasms/drug therapy ; Adjuvants, Immunologic/therapeutic use ; Immunotherapy ; Mitogen-Activated Protein Kinase Kinases
    Chemical Substances Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Programmed Cell Death 1 Receptor ; Adjuvants, Immunologic ; Mitogen-Activated Protein Kinase Kinases (EC 2.7.12.2) ; BRAF protein, human (EC 2.7.11.1)
    Language English
    Publishing date 2024-01-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2024.113561
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.

    Richtig, Erika / Nguyen, Van A / Koelblinger, Peter / Wolf, Ingrid / Kehrer, Helmut / Saxinger, Werner / Ressler, Julia M / Weinlich, Georg / Meyersburg, Damian / Hafner, Christine / Jecel-Grill, Elisabeth / Kofler, Julian / Lange-Asschenfeldt, Bernhard / Weihsengruber, Felix / Rappersberger, Klemens / Svastics, Nina / Gasser, Klaus / Seeber, Arno / Kratochvill, Franz /
    Nagler, Sophie / Mraz, Bernhard / Hoeller, Christoph

    Melanoma research

    2023  Volume 34, Issue 2, Page(s) 142–151

    Abstract: Objective: The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real- ... ...

    Abstract Objective: The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma.
    Methods: This multicenter, open-label, non-interventional, post-approval, observational study investigated the effectiveness of dabrafenib plus trametinib prescribed in day-to-day clinical practice to patients ( N  = 79) with BRAF V600-mutant unresectable/metastatic melanoma with M1c disease (American Joint Committee on Cancer staging manual version 7), ECOG > 1, and elevated serum lactate dehydrogenase (LDH). The primary endpoint was 6-, 12- and 18-month progression-free survival (PFS) rates. Secondary endpoints were median PFS, disease control rate and overall survival (OS).
    Results: The 6-, 12- and 18-month PFS rates were 76%, 30.6% and 16.2%, respectively. Subgroup analysis showed a significant PFS benefit in the absence of lung metastasis. The median PFS and OS were 9.1 (95% CI, 7.1-10.3) months and 17.9 (95% CI, 12.7-27.8) months, respectively. The 12- and 24-month OS rates were 62.7% and 26.8%, respectively. Subgroup analyses showed significant OS benefits in the absence of bone or lung metastasis and the presence of other metastases (excluding bone, lung, brain, liver and lymph nodes). Furthermore, S100 and Eastern Cooperative Oncology Group performance status (ECOG PS) showed a significant impact on survival. No new safety signals were observed.
    Conclusion: Despite an unselected population of melanoma patients with higher M1c disease, ECOG PS > 1 and elevated LDH, this real-world study demonstrated comparable efficacy and safety with the pivotal phase 3 clinical trials for dabrafenib-trametinib.
    MeSH term(s) Humans ; Melanoma/drug therapy ; Melanoma/genetics ; Prospective Studies ; Proto-Oncogene Proteins B-raf/genetics ; Skin Neoplasms/drug therapy ; Lung Neoplasms ; Imidazoles ; Oximes ; Pyridones ; Pyrimidinones
    Chemical Substances dabrafenib (QGP4HA4G1B) ; trametinib (33E86K87QN) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; BRAF protein, human (EC 2.7.11.1) ; Imidazoles ; Oximes ; Pyridones ; Pyrimidinones
    Language English
    Publishing date 2023-12-13
    Publishing country England
    Document type Multicenter Study ; Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1095779-0
    ISSN 1473-5636 ; 0960-8931
    ISSN (online) 1473-5636
    ISSN 0960-8931
    DOI 10.1097/CMR.0000000000000948
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3378: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top